Home › Stocks › Chemicals stocks › UPL
Chemicals stocks Valuation research

UPL fair value — a global crop-protection giant

UPL sells crop-protection chemicals and seeds in more than 130 countries. A global inventory glut pushed it into a loss in FY2024; recovery and debt reduction are now the story.

FairStocks Research
Updated 15 Nov 2026 · 4 min read
| NSE: UPL ₹559
On this page ▾
  1. The business
  2. What the market assumes
  3. The ten-year record
  4. How it is valued
  5. What decides the value
  6. What could go wrong
  7. The full valuation
  8. Questions
UPL (UPL) fair value — is it overvalued? Price ₹559, P/E 25.0, P/B 1.36, ROE —. Based on 10 years of reported financials. FairStocks.
UPL at a glance. Share price, P/E, P/B and the ten-year revenue trend, from filed accounts. Updated 15 Nov 2026.
In 30 seconds

The market expects much less from UPL than it has delivered before.

At today’s share price, buyers are assuming UPL grows about 0% a year, forever. Over the last ten years it actually grew about 6% a year. That is a big step down from its own record — in other words, that it stops growing altogether. Either the market can see a problem that the published accounts do not show yet, or it is expecting a slowdown that has not happened.

  • How it is valued: Discounted cash flow.
  • What the price assumes: 0% growth, against 6% the model takes from its own record.
  • Ten-year record: Between FY2019 and FY2026, UPL's revenue went from ₹21,837 crore to ₹51,839 crore — it compounded at about 13% a year over 7 years.
  • Biggest swing factor: Global farm demand. Main risk: Chinese generics.
Price
₹559
Market cap
₹0.47L Cr
P/E
25.0
P/B
1.36
See UPL's fair value and the full DCFEvery step of the UPL working, the scenarios and the report Free during launch →

01From Mumbai to the world's farms

UPL, controlled by the Shroff family, is one of the world's largest makers of generic crop-protection products — herbicides, insecticides and fungicides — with a large presence in Latin America, North America, Europe and India.

It bought Arysta LifeScience in 2019, which roughly doubled its size, and owns seeds business Advanta. The acquisition added significant debt.

02What the market is assuming

Work backwards from today's share price and you can see what buyers are quietly taking for granted. Here is the growth that price implies for UPL, next to what the model assumes from the company's own record.

Market expects
0%
growth priced into today's price
Model assumes
6%
growth the model assumes

The further apart these two numbers are, the bigger the bet a buyer at today's price is making.

03UPL's record, in plain numbers

Between FY2019 and FY2026, UPL's revenue went from ₹21,837 crore to ₹51,839 crore — it compounded at about 13% a year over 7 years. It reported a net loss in FY2024, and closed the period with net profit of ₹2,220 crore. In FY2026 it kept 4.3% of revenue as net profit — against a low of -4.4% in FY2024 and a high of 9.6% in FY2022. The latest year added 11.2% to revenue, close to its own long-run pace.

Reading the record. The FY2020 revenue jump reflects the Arysta acquisition; the FY2024 loss came from a global destocking cycle and falling prices.
Revenue₹0.22L → ₹0.52L Cr
1920212223242526
Earnings per share₹28.4 → ₹22.3
1920212223242526
Return on equity12.9% → 15.3%
20212223242526

Revenue and earnings per share in ₹, return on equity and leverage as ratios — all from the filed statements.

Revenue and net profit by year (₹ crore)
YearRevenueNet profitMargin
FY201921,8371,5197.0%
FY202035,7562,1786.1%
FY202138,6943,4959.0%
FY202246,2404,4379.6%
FY202353,5764,4148.2%
FY202443,098-1,878-4.4%
FY202546,6378201.8%
FY202651,8392,2204.3%

04How UPL gets valued — and why

Discounted cash flow

This business is valued on the cash it is expected to generate, discounted back at its cost of capital — with growth taken from its own ten-year record rather than from guidance.

05What decides UPL's value

Global farm demand

Crop prices and planting drive sales.

Channel inventory

Distributor stock levels swing volumes.

Debt reduction

Lower debt cuts interest costs.

Advanta seeds

A faster-growing, higher-margin business.

06What could go wrong

  • Chinese generics. Low-priced Chinese products pressure prices.
  • Leverage. High debt magnifies downturns.
  • Weather and currencies. Brazil and Argentina conditions matter a lot.

07What the full UPL valuation shows

Model value per share
₹0,000
Upside
+00%
Call
XXXX

Sign in free to see the complete UPL valuation

  • ✓Fair value per share — from a ten-year discounted cash flow, every step shown
  • ✓The Workbench — change revenue growth, the discount rate or terminal growth and watch UPL's value move
  • ✓Bull, base and bear cases — and exactly which assumptions move between them
  • ✓Peer comparison — against Coromandel, PI Industries and other agri-input companies
  • ✓Downloadable report — the full write-up, yours to keep
See UPL's fair value and the full DCF — free
Free during launch · unlimited valuations · no card required

08Questions people ask about UPL

What does UPL make?

Herbicides, insecticides, fungicides and seeds.

Why did UPL report a loss in FY2024?

Distributors cut inventories worldwide and prices fell.

What was the Arysta deal?

UPL's 2019 acquisition of Arysta LifeScience, which roughly doubled its size.

Is UPL overvalued?

At ₹559 the market is pricing in roughly 0% sustained growth, against the ~6% its own record supports. That is less than it has delivered — on these numbers the market is asking the business for less than its own record, which usually means it doubts the record repeats.

What is the intrinsic value of UPL?

It is computed from the filed financial statements using the method that fits this business (discounted cash flow), with every assumption shown alongside the result. The per-share figure and the full working are in the report.

How much debt does UPL carry?

Debt to equity stands at 0.63, down from 0.97 at the start of the period — the balance sheet is a core input to the cost of capital used here.

About this research

Written by the FairStocks research team from UPL's filed accounts and last reviewed 5 Oct 2026; the figures refresh as new results are filed. Every valuation uses the method that fits the business and shows its assumptions — see a fully worked example or the valuation guides. Educational research, not investment advice.

See UPL's fair value and the full DCFUnlock free